Sernova Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Cynthia Pussinen

Chief Executive Officer (CEO)

CA$2.6m

Compensación total

Porcentaje del salario del CEO	3.6%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Cynthia Pussinen en comparación con los beneficios de Sernova?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jan 31 2024	n/a	n/a	-CA$41m
Oct 31 2023	CA$3m	CA$92k	-CA$39m

Compensación vs. Mercado: La compensación total de Cynthia($USD1.88M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Cynthia con los resultados de la empresa.

CEO

Cynthia Pussinen

less than a year

Permanencia

CA$2,574,600

Compensación

Ms. Cynthia Pussinen is Chief Executive Officer & Director at Sernova Corporation from September 2023. She served as an Executive Vice President of Technical Operations and Supply Chain at Actinium Pharmac...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	sin datos
Modestus Obochi	Chief Business Officer	less than a year	CA$996.01k	sin datos
Frank Shannon	Vice President of Clinical Development & Regulatory Affairs	2.8yrs	CA$463.26k	sin datos
Nicholas Rossettos	Interim Chief Financial Officer	less than a year	sin datos	sin datos
Douglas Maret	Chief Science Officer	no data	sin datos	sin datos
Christopher Barnes	Vice President of Investor Relations	2.4yrs	CA$352.33k	sin datos

0.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de PSH no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	sin datos
James Parsons	Independent Director	12.1yrs	CA$183.27k	0.094% CA$ 57.6k
Norman C. Wong	Member of Scientific Advisory Board	17.8yrs	sin datos	sin datos
Jannette Dufour	Member of Scientific Advisory Board	17.8yrs	sin datos	sin datos
George King	Member of Scientific Advisory Board	no data	sin datos	sin datos
Clive Patience	Member of Scientific Advisory Board	17.4yrs	sin datos	sin datos
Brett Whalen	Independent Chairman	1.1yrs	CA$170.23k	0.87% CA$ 536.2k
Steven Paraskevas	Member of Scientific Advisory Board	13.4yrs	sin datos	sin datos
David Lillicrap	Member of Scientific Advisory Board	5.3yrs	sin datos	sin datos
Anke Schulte	Member of Global Advisory Board	3.8yrs	sin datos	sin datos
Stephen Sangha	Independent Director	1.1yrs	CA$158.36k	4.01% CA$ 2.5m
Sam Wiseman	Member of Scientific Advisory Board	3.1yrs	sin datos	sin datos

5.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de PSH se considera experimentada (5.3 años de antigüedad promedio).

Sernova Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Recent updates

New major risk - Share price stability

New minor risk - Market cap size

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

New minor risk - Share price stability

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought €51k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad